Portal de Periódicos da CAPES

Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients

2008; Wiley; Volume: 82; Issue: 3 Linguagem: Inglês

10.1111/j.1600-0609.2008.01184.x

1600-0609

Silvia Mangiacavalli, Gian-Matteo Pica, Marzia Varettoni, Mario Lazzarino, Alessandro Corso,

Protein Degradation and Inhibitors

European Journal of HaematologyVolume 82, Issue 3 p. 240-241 Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients Silvia Mangiacavalli, Silvia Mangiacavalli Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorGianMatteo Pica, GianMatteo Pica Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorMarzia Varettoni, Marzia Varettoni Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorMario Lazzarino, Mario Lazzarino Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorAlessandro Corso, Alessandro Corso Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this author Silvia Mangiacavalli, Silvia Mangiacavalli Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorGianMatteo Pica, GianMatteo Pica Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorMarzia Varettoni, Marzia Varettoni Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorMario Lazzarino, Mario Lazzarino Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this authorAlessandro Corso, Alessandro Corso Division of Hematology, IRCCS Fondazione Policlinico ‘San Matteo’, University of Pavia, Pavia, ItalySearch for more papers by this author First published: 27 January 2009 https://doi.org/10.1111/j.1600-0609.2008.01184.xCitations: 6 Dr Silvia Mangiacavalli, Division of Hematology, Fondazione Policlinico San Matteo, Via Golgi 19, 27100 Pavia, Italy. Tel: +3 90 382503595; Fax: +3 90 382502250; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Reece DE, Management of multiple myeloma: the changing landscape. Blood Rev. 2007; 21: 301– 14. Epub 2007 Aug 29 2 Attal M, Harousseau JL. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol. 2007; 20: 747– 59. 3 Facon T, Darre S. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best Pract Res Clin Haematol. 2007; 20: 737– 46. Review. 4 De Rossi A, et al. Focus on Fotemustine. J Exp Clin Cancer Res 2006; 25: 461– 8. 5 Dumontet C, et al. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003; 14: 615– 22. 6 Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467– 73. Citing Literature Volume82, Issue3March 2009Pages 240-241 ReferencesRelatedInformation